Recent

% | $
Quotes you view appear here for quick access.

Trius Therapeutics, AŞ Message Board

galaberge 12 posts  |  Last Activity: Feb 2, 2016 10:36 AM Member since: Mar 5, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Aquinox is currently developing AQX-1125 as treatment in bladder pain syndrome/interstitial cystitis (BPS/IC)

    Potential market for BPS/IC is estimated to affect between 5 and 12 million people in the United States per year. Most BPS/IC patients continue to suffer this debilitating condition, despite treatment with existing therapies. Most current therapies and those in development are focused solely on symptomatic relief of BPS/IC.

    AQX-1125 could reach in U.S. alone peak revenue of $1.5-billion

    Pfizer and Johnson & Johnson own a significant amount in the company's shares.

    About AQX-1125

    All the clinical development utilize AQX-1125 tablets in an once-a-day dosing and has low plasma protein binding,being not metabolized and easily excreted unmetabolized in both urine and feces as per the first 7 clinical trials.

    -AQX-1125, Aquinox's lead drug candidate, is a small molecule activator of SHIP1, which is a regulating component of the PI3K cellular signaling pathway. By increasing SHIP1 activity

    -AQX-1125 accelerates a natural mechanism that has evolved to maintain homeostasis of the immune system and reduce immune cell activation and migration to sites of inflammation

    -AQX-1125 has demonstrated preliminary safety and favorable drug properties for once daily oral administration in multiple preclinical studies and seven completed clinical trials.

    Sentiment: Strong Buy

  • and is the first system that could be used by blood banks to destroy viruses and bacteria in donated blood plasma, potentially making transfusions safer.

    The U.S. Food and Drug Administration (FDA) has approved the INTERCEPT Blood System for platelets. The INTERCEPT platelet system is approved for ex vivo preparation of pathogen-reduced apheresis platelet components in order to reduce the risk of transfusion-transmitted infection (TTI), including sepsis, and to potentially reduce the risk of transfusion-associated graft versus host disease (TA-GVHD).

    The approval marks the first time that a system to inactivate pathogens in platelet components will be available in the United States. The FDA approved the INTERCEPT Blood System for plasma on December 16. The INTERCEPT systems for both plasma and platelets use the same illumination device, the same active compound (amotosalen) and very similar production steps.

    Long and strong CERS

    Sentiment: Strong Buy

  • “We are probably at a point where the individual company fundamentals matter,” she says. “We will see bifurcation: those with good fundamentals, a good pipeline, will continue to do well; the others less so.”

    “It will increasingly be a stockpicker’s market,” she adds

    That suits specialist investors such as Mr Borho. “Going into January, the biotech sector is not going to be a consensus long for generalist investors,” he says. “That’s a set-up I like, because there’s the opportunity for lots of surprise on the upside....”

    Long and strong HZNP

    Sentiment: Strong Buy

  • Reply to

    New gout treatment, Zurampic by AstraZeneca

    by shirazi2001us Dec 23, 2015 3:00 PM
    galaberge galaberge Dec 23, 2015 3:51 PM Flag

    Zurampic is not a competitor of

    Just check this :"An advisory committee to the US Food and Drug Administration (FDA) voted 10 to 4 to recommend lesinurad (Zurampic, AstraZeneca) 200 mg once daily for the treatment of gout-associated hyperuricemia, in combination with a xanthine oxidase inhibitor (XOI).

    The advisory committee voted unanimously that the company presented substantial evidence in favor of the drug's efficacy; the panel voted with narrow margins (7 yes, 6 no, 1 abstention) in favor of the drug's safety."The Committee's positive recommendation for lesinurad is an encouraging step for patients suffering from the debilitating effects of gout," Sean Bohen, MD, PhD, Executive vice president of Global Medicines Development and chief medical officer, AstraZeneca, said in a news release. "We look forward to the outcome of the FDA's review and the opportunity to provide a new treatment option that, when combined with a xanthine oxidase inhibitor, addresses both the under-excretion and over-production of uric acid, the underlying causes of gout."

    and

    "The narrow therapeutic index of this drug really does concern me. If we have it out in general use, we're either going to learn that it's safe, or we'll learn that it's not safe and take it off the market later," said temporary voting committee member Peter J. Kaboli, MD, FACPP, FHM, from University of Iowa Carver College of Medicine and Iowa City Veterans Affairs Healthcare System, both in Iowa City, Iowa. Dr Kaboli said that he's concerned that it may help some patients but harm others. There were a total of 17 deaths...."

    Read carefully the full article: " medscapeDOTcom/viewarticle/853201 "

    Long and strong HZNP

    Sentiment: Strong Buy

  • galaberge by galaberge Dec 23, 2015 3:04 PM Flag

    Have fun in watching this very hilarious video..." youtubeDOTcom/watch?v=hKWmFWRVLlU "

    Long and strong HZNP

    Sentiment: Strong Buy

  • Jeffrey W Sherman, Horizon Pharma's EVP and Chief Medical Officer, recently acquired 30,442 shares of the company. Sherman now owns 135,574 shares of the company.

    The stock option vests in 48 equal monthly installments following January 2, 2013, the date of grant. The option vested in 48 equal monthly installments from the date of grant and is fully vested and exercisable.The buys took place at prices ranging from $2.40 to $4.96 per share.

    The information was disclosed in a filing to the SEC; see the filing : " irDOThorizon-pharmaDOTcom/secfiling.cfm?filingID=1209191-15-85629&CIK=1492426 "

    Long and strong HZNP

    Sentiment: Strong Buy

  • Brean Capital issued a company update on Horizon Pharma PLC (NASDAQ: HZNP) after the pharmaceutical company announced the acquisition of Crealta Holdings LLC. Currently, Brean rates Horizon as a Buy and raised their price target from $31 to $32.

    Acquisition Justification
    Brean Capital believes that the acquisition is accretive for 4 reasons:

    1. Crealta is expected to bring in $70-80 million in revenue and $45-50 million in EBITDA for 2016.
    2. Sales and margins may improve due to Crealta expanding Horizon’s orphan business unit.
    3. The Crealta acquisition will allow Horizon to integrate a new rheumatology sales force.
    4. The deal increases the diversification of Horizon’s product portfolio.
    In aTimothy P. Walbert, chairman, president and CEO of Horizon Pharma said, “The Crealta acquisition further diversifies our portfolio of medicines and aligns with our focus of acquiring value-enhancing, clinically differentiated, long-life medicines that treat orphan diseases. We have a proven track record of strong commercial execution and the ability to generate volume growth for clinically differentiated medicines.”

    Long and strong HZNP

    Sentiment: Strong Buy

  • 5-star analyst Marc Goodman from UBS reiterated a BUY on $HZNP. Marc has a 68% success rate

    Check the link : " tipranksDOTcom/analysts/marc-goodman "

    Long and strong HZNP

    Sentiment: Strong Buy

  • Reply to

    Does Crelta worth $510m? Sure it does.

    by cash_is_king_now Dec 13, 2015 12:56 AM
    galaberge galaberge Dec 13, 2015 1:02 PM Flag

    Thanks a lot for your pertinent,intelligent and factual points in your 2 posts. Congrats fellow long.

    Long and strong HZNP

    Sentiment: Strong Buy

  • Reply to

    The best deal for HZNP would be SUCAMPO SCMP

    by galaberge Dec 7, 2015 3:59 PM
    galaberge galaberge Dec 7, 2015 4:05 PM Flag

    Google the presentation of SCMP at Piper Jaffray : " sucampoDOTcom/wp-content/uploads/2015/12/Piper-Conference-Dec-2015-Deck-for-PresentationDOTpdf "

    Sentiment: Strong Buy

  • It would be immediately accretive to revenue, earnings and operating cash flows.

    Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide. Sucampo has one marketed product – AMITIZA – and a pipeline of product candidates in clinical development. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan, Switzerland and the U.K.

    Long and strong HZNP

    Sentiment: Strong Buy

  • galaberge galaberge Nov 15, 2015 7:06 AM Flag

    I fully agree with what you say. It's time for HZNP to step out of this mess and go to buy another company. We loose our time...and our money with DEPO